N-terminal pro-brain natriuretic peptide in decompansated ventricular septal defect

Archives of Medical Science

Volumn 5, Issue 3, 2009, Pages 376-382

  Baghdady, Yasser ^a   Kamel, Yasser ^a   Elwan, Amany ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Cardiac decompensation; NT proBNP; Ventricular septal defect

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INOTROPIC AGENT;

ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART LEFT ATRIUM; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART RIGHT VENTRICLE PRESSURE; HEART RIGHT VENTRICLE VOLUME; HEART VENTRICLE SEPTUM DEFECT; HUMAN; LUNG ARTERY PRESSURE; MALE; PRESCHOOL CHILD; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SCORING SYSTEM;

EID: 73449143824     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998; 135: 825-832.
2. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (NT-PROBNP) concentrations. Lancet 2000; 355: 1126-30.
3. Clerico A, Emdin M. Diagnostic accurancy and prognostic relevance of the measurement of cardiac natriuretic peptides a review. Clin Chem 2004; 50: 33-50.
4. De Bold AJ, Ma KK, Zhang Y, et al. The physiological and pathophysiological modulation of the endocrine function of the heart. Can J Physiol Pharmacol 2001; 79: 705-14.
5. Kelly R, Struthers AD. Are natriuretic peptides clinically useful as markers of heart failure? Ann Clin Biochem 2001; 38: 94-102.
6. Maisel A, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161-7.
7. Talwar S, Siebenhofer A, Williams B, Ng LL. Influence of hypertension, left ventricular hypertrophy, and left ventricular systolic dysfunction on plasma N terminal pro BMP. Heart 2000; 83: 278-82.
8. Wijbenga JA, Balk AH, Boosma F, Man in't Veld AJ, Hall C. Cardiac peptides differ in their response to exercise. Implications for patients with heart failure. Eur Heart J 1999; 20: 1424-8.
9. Vanderheyden M, Bartunek J, Claevs G, et al. Head to head comparison of N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in patients with/without left ventricular systolic dysfunction. Clin Biochem 2006; 39: 640-5.
10. Masson S, Vago T, Baldi G, et al. Comparative measurement of N-terminal-brain natriuretic peptide and brain natriuretic peptide in ambulatory patients with heart failure. Clin Chem Lab Med 2002; 40: 761-3.
11. Cowie MR, Mendez GF. BNP and congestive heart failure. Prog Card Vasc 2002; 44: 293-321.
12. Ross RD. Grading the severity of congestive heart failure in infants. Pediatr Cardiol 1992; 13: 72-5.
13. Reithmann C, Reber D, Kozlik-Feldmann R, et al. A post-receptor defect of adenylyl cyclase in severely failing myocardium from children with congenital heart disease. Eur J Pharmacol 1997; 330: 79-86.
14. Läer S, Mir TS, Behn F, et al. Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. Am Heart J 2002; 143: 916-22.
15. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 1989; 2: 358-67.
16. Otto CM. Echocardiographic evaluation of left and right ventricular systolic function. In: Otto CM (ed.). Textbook of clinical echocardiography. WB Saunders, Philadelphia 2000; 100-28.
17. Kimball TR, Daniels SR, Meyer RA, et al. Relation of symptoms to contractility and defect size in infants with ventricular septal defect. Am J Cardiol 1991; 67: 1079.
18. Ge Z, Zhang Y, Kang W, et al. Non invasive evaluation of right ventricular and pulmonary artery systolic pressure in patients with ventricular septal defects: simultaneous study of doppler and catheterization data. Am Heart J 1993; 125: 1073.
19. Abassi Z, Karram T, Ellaham S, Winaver J, Hoffman A. Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharmacol Ther 2004; 102: 223-41.
20. Baxter GF. The natriuretic peptides: an introduction. Basic Res Cardiol 2004; 99: 71-5.
21. Koch A, Singer H. Normal values of B type natriuretic peptide in infants, children, and adolescents. Heart 2003; 89: 875-8.
22. Gotze JP, Kastrup J. Plasma pro-brain natriuretic peptides are strong biochemical markers in clinical cardiology. Scand J Clin Lab Invest 2001; 61 (Suppl 234): 47-51.
23. Ootaki Y, Yamaguchi M, Yoshimura N, et al. Secretion of A-type and B-type natriuretic peptides into the blood-stream and pericardial space in children with congenital heart disease. J Thorac Cardiovasc Surg 2003; 126: 1410-6.
24. Manatomo T, Kenji H, Masamichi T, et al. Paradoxical relationship between B-type natriuretic peptide and pulmonary vascular resistance in patients with ventricular septal defect and concomitant severe pulmonary hypertension. Pediatr Cardiol 2008; 29: 65-9.
25. Suda K, Matsumara M, Matsumoto M. Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int 2003; 45: 249-54.
26. Ozhan H, Albayrak S, Uzun H, Ordu S, Kaya A, Yazic M. Correlation of plasma B-type natriuretic peptide with shunt severity in patients with atrial or ventricular septal defect. Pediatr Cardiol 2007; 28: 272-5.